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Abstract
Background: Duchenne muscular dystrophy (DMD) is a common X-linked neuromuscular disease that
causes progressive muscle weakness and leads to early death. Those affected often present with muscle
weakness as their primary symptom and generally develop scoliosis, respiratory, and cardiac complications as
well. In the natural course of DMD, affected males lose ambulation at a mean age of 9.5 years and death
generally ensues in the second or third decades of life. There is no curative treatment and corticosteroids are
the only approved therapy for slowing the progression of the disease. While much research has been done
assessing efficacy of corticosteroid treatment, there is still great uncertainty concerning the optimum dosing
schedule.
Method: An extensive search of medical literature was conducted with Medline-OVID, CINAHL, Web of
Science and MDConsult using key terms: Duchenne muscular dystrophy, corticosteroids or adrenal cortex
hormones, and drug administration schedule or alternate. Studies that assessed efficacy of alternate-day
dosing and intermittent dosing regimens were selected and compared to data collected on daily dosing
regimens. Articles that met inclusion criteria were chosen and assessed for quality using the GRADE method.
Results: Four studies met inclusion criteria and were included in this systematic review. Two studies focused
on alternate-day dosing regimens and two studies evaluated intermittent corticosteroid dosing schedules.
While all regimens were found to prolong ambulation and slow progression of DMD when compared to the
natural course of the disease, daily dosing seems to be most effective. Alternate-day and intermittent dosing
schedules also prolong independent ambulation but not to the extent that daily corticosteroid therapy did.
Lastly, significant scoliosis and declines in respiratory function were delayed in patients treated with all
corticosteroid dosing regimens.
Conclusion: Corticosteroids have shown to slow progression of DMD by prolonging ambulation, postponing
or preventing the development of scoliosis, and delaying respiratory function decline. Evidence suggests that
daily corticosteroid therapy is most efficacious in managing DMD but with highest rates of moderate to severe
side effects. A recommendation can be made for the use of alternate-day corticosteroid dosing initiated early
in the disease process (age 2-4 years). More research is needed to determine whether or not alternative
regimens can be as effective as daily treatment and at what age to initiate therapy.
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Abstract   
Background: Duchenne muscular dystrophy (DMD) is a common X-linked 
neuromuscular disease that causes progressive muscle weakness and leads to early death. 
Those affected often present with muscle weakness as their primary symptom and 
generally develop scoliosis, respiratory, and cardiac complications as well. In the natural 
course of DMD, affected males lose ambulation at a mean age of 9.5 years and death 
generally ensues in the second or third decades of life. There is no curative treatment and 
corticosteroids are the only approved therapy for slowing the progression of the disease. 
While much research has been done assessing efficacy of corticosteroid treatment, there 
is still great uncertainty concerning the optimum dosing schedule.  
 
Method: An extensive search of medical literature was conducted with Medline-OVID, 
CINAHL, Web of Science and MDConsult using key terms: Duchenne muscular 
dystrophy, corticosteroids or adrenal cortex hormones, and drug administration schedule 
or alternate. Studies that assessed efficacy of alternate-day dosing and intermittent dosing 
regimens were selected and compared to data collected on daily dosing regimens. 
Articles that met inclusion criteria were chosen and assessed for quality using the 
GRADE method. 
 
Results: Four studies met inclusion criteria and were included in this systematic review. 
Two studies focused on alternate-day dosing regimens and two studies evaluated 
intermittent corticosteroid dosing schedules. While all regimens were found to prolong 
ambulation and slow progression of DMD when compared to the natural course of the 
disease, daily dosing seems to be most effective. Alternate-day and intermittent dosing 
schedules also prolong independent ambulation but not to the extent that daily 
corticosteroid therapy did. Lastly, significant scoliosis and declines in respiratory 
function were delayed in patients treated with all corticosteroid dosing regimens. 
 
Conclusion:  Corticosteroids have shown to slow progression of DMD by prolonging 
ambulation, postponing or preventing the development of scoliosis, and delaying 
respiratory function decline. Evidence suggests that daily corticosteroid therapy is most 
efficacious in managing DMD but with highest rates of moderate to severe side effects. A 
recommendation can be made for the use of alternate-day corticosteroid dosing initiated 
early in the disease process (age 2-4 years).  More research is needed to determine 
whether or not alternative regimens can be as effective as daily treatment and at what age 
to initiate therapy.   
 
Keywords: Duchenne muscular dystrophy, corticosteroids, dosing schedule, prolonging 
ambulation 
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Optimal Dosing Regimen of Corticosteroids in the Treatment of Duchenne 
Muscular Dystrophy 
BACKGROUND 
 Duchenne muscular dystrophy (DMD) is an X-linked progressive neuromuscular 
disorder that affects 1 in 3600 male live births.1,2 DMD is caused by a defect in the gene 
responsible for producing dystrophin, which “provides reinforcement to the sarcolemma 
and stabilizes the glycoprotein complex, thereby shielding it from degradation.”3 Without 
dystrophin the glycoprotein complex is susceptible to digestion by proteases leading to 
degeneration and necrosis of muscle fibers and resulting in significant muscle weakness.3  
 Muscle weakness is the primary symptom and onset usually occurs between the 
ages of two and three years.4 Clinically, weakness is generally seen in the lower 
extremities and in proximal muscles first.  Muscle weakness often results in difficulties 
rising from the floor, walking, running, and climbing stairs.5 Affected children may also 
present with calf hypertrophy, lumbar lordosis, Gower’s sign, and a waddling gait.3 
 In the natural course of DMD, independent ambulation is generally lost between 
the ages of 6 and 13 (mean age of 9.5 years).6 Studies show that the prevalence and 
severity of scoliosis is much lower in DMD patients treated with corticosteroids. King et 
al7 found that not only were patients treated with corticosteroids ambulant 3.3 years 
longer, they were also less likely to develop scoliosis (31 to 91%) when compared to 
untreated boys. In addition to the development of scoliosis, progressive respiratory, 
cardiac, and orthopedic complications are common in the second decade of life and 
eventually lead to premature death in late teens or twenties.6, 5 
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 Although there is currently no curative treatment for DMD, corticosteroid therapy 
has been approved as the only pharmacological intervention known to slow progression 
of the disease and prolong independent ambulation.6,8,9 The exact mechanism is unknown 
but “it has been hypothesized that corticosteroids have anti-inflammatory and 
immunosuppressive actions, promote myoblast proliferation, and reduce muscle 
necrosis.”10 Furthermore, studies have shown that corticosteroids are effective in slowing 
the progression of DMD. There are currently several dosing regimens options (i.e., daily, 
alternate-day, intermittent, and weekend only) but the question remains as to which is the 
best and at what age to begin therapy.  
METHODS 
An extensive search of medical literature was conducted using Medline-OVID, 
CINAHL, Web of Science, and MDConsult. Search terms included Duchenne muscular 
dystrophy, corticosteroids or adrenal cortex hormones, and drug administration schedule 
or alternate. The search was narrowed to include English language articles on human 
subjects. Studies that focused on daily, alternate-day, and intermittent corticosteroid 
dosing treatments were included. Articles matching these criteria were evaluated using 
the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) 
method.11 
RESULTS 
  The initial search of medical literature yielded 19 articles available for review.  
The studies were examined and those found to focus on alternate-day and intermittent 
corticosteroid dosing regimens that met inclusion criteria were selected and compared to 
 
8 
data collected assessing daily corticosteroid therapy.  There were two alternate-day 
dosing12,13 studies and two intermittent dosing14,15 studies chosen. See Table 1. 
Yilmaz et al Study 
  The observational cohort study12 compared the effectiveness of alternate-day 
dosing of prednisolone to untreated patients with DMD in prolonging independent 
ambulation, onset of scoliosis, muscle strength, 10-m walking, and ankle contractures. Of 
most importance to this review are age at which ambulation was lost and onset of 
scoliosis. For this study, authors reviewed data from 66 DMD boys who had received 
alternate-day prednisolone therapy and 22 DMD boys in the control group who received 
no treatment. Participants in the treatment group (mean age 6.8 + 2.1 years, range 2.5-
12.5 years) received oral prednisolone 0.75 mg/kg on alternate days and vitamin D 600-
1200 units/day daily. Members of both the treatment and control groups received a 
calcium-rich diet as well. Control subjects (mean age 7.0 + 1.3 years, range 5-9 years) 
were taken from an earlier cohort group so age-matching could be performed. There was 
no statistically significant difference between the mean ages of the treatment and control 
groups.12 
 Each participant underwent an initial evaluation and was re-examined every 6 
months. At the time of initiation, all were instructed to engage in specific strengthening 
and stretching exercises, posture and breathing exercises, and positioning and nighttime 
ankle-foot (AFO) use. Length of follow-up was 2.75 + 0.1 years (range 1.5-5 years).12 
 When evaluating treatment efficacy for DMD, the age at which ambulation is lost 
is commonly a primary response of interest. Participants in the therapy group of this 
study lost the ability to walk independently at 10.0 years + 1.5 years (range 7-14 years). 
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Those in the control group lost independent ambulation at 8.6 years + 2.6 years (range 6-
11). While there were no DMD boys ambulant beyond the age of 11 years in the control 
group, there were 14 ambulant from the therapy group at age 12 and three boys still 
ambulant at the age of 13.12 
 In the natural course of DMD, the majority of patients develop scoliosis (often 
after ambulation is lost) that can have severe negative effects on respiratory function and 
quality of life. Authors of this study found that none of the therapy group patients had 
scoliotic curves greater than 24° at the end of the follow-up period, but there were seven 
in the control group that had curves > 45° by the mean age of 11.7 years + 0.8 years 
(range 9-16 years).12  
 Interestingly enough, participants of the therapy group experienced increases in 
10-m walking time, decreased muscle strength of upper and lower extremities after 12 
months of therapy, and increased rates of ankle contractures in comparison to the control 
group. These results may indicate that exercises play an important role in maintaining 
muscle strength. Despite these deficits, patients treated with corticosteroids remained 
ambulant longer than those who did not receive treatment.12 
Merlini et al Study 
 This long-term prospective observational study13 assessed the value of early 
administration of alternate-day corticosteroid treatment in five boys with DMD. The 
primary outcome of interest was prolongation of independent ambulation but authors also 
evaluated the ability to rise from the floor, respiratory and cardiac function, as well as 
significant side effects of corticosteroid treatment.13 
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 Researchers began this study in 1996 by enrolling eight DMD patients between 
the ages of 2 and 4years. The parents of five participants chose alternate-day 
corticosteroid treatment and three opted for no treatment. Corticosteroid therapy was 
prednisone 0.75 mg/kg daily for 2 weeks then 1.25 mg/kg every other day (max dose of 
50 mg). This regimen continued for 3 years at which time it was switched to deflazacort 
to lower risk of weight gain.16 The alternate day deflazacort (1.5 mg/kg every other day 
with a max dose of 60 mg) was then progressively tapered to 0.7-1.0 mg/kg every other 
day around the ages of 12-14 years. Participants were also given supplemental vitamin D3 
400 units and calcium 1250 mg by mouth daily. The authors hypothesized that beginning 
treatment at a younger age, before significant motor loss was evident, would provide 
more benefits due to the progressive nature of the disease.13 
 Participant monitoring was performed every 3-6 months and researchers 
evaluated muscle function via several timed tests, respiratory function by forced vital 
capacity (FVC), and side effects of treatment through parent interviews and clinical 
exams. The primary outcome of interest was prolongation of independent walking. One 
boy in the therapy group and one in the control group were followed just until they lost 
independent ambulation at the ages of 10 years both. The two remaining participants in 
the control group were lost to follow-up when they lost the ability to rise from the floor at 
the ages of 8 and 9.5 years. The remaining four participants in the therapy group were 
followed for 14 years. At the time of the last follow-up, all four in the therapy group were 
fully and independently ambulatory (aged 16-18) and three were still able to climb stairs. 
The fourth had lost the ability to climb stairs at the age of 17 years. Two of the remaining 
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four boys in the therapy group had lost the ability rise from the floor at the ages of 12.5 
and 15.5 years, a task that is often the first motor skill lost in the course of DMD.13,17 
 Another important outcome of interest, respiratory function, was also routinely 
evaluated. Forced vital capacity (FVC) was ascertained with electronic spirometry. 
Researchers found that two of the remaining participants in the treatment group had 
normal FVCs and the other two had moderately reduced pulmonary function based on 
their FVCs at the final follow-up. A summary of FVC results can be found in Table 2. 
Researchers found a similar trend with respect to muscle strength in the remaining 
participants of the therapy group. Muscle strength in all four increased somewhat 
between the ages of 5 and 9-10 then began to decline. This decline was most dramatic in 
knee extensor muscles. Participants were also assessed by a cardiologist annually. Based 
on physical exam, electrocardiograms and echocardiograms, only one participant in the 
therapy group was found to have a mildly reduced left ventricular ejection fraction (EF) 
of 50%. The remaining three patients had left ventricular EFs between 57-60%. 
Cardiologists determined a left ventricular EF below 50% as indicative of systolic 
dysfunction, and <45% graded as moderate or severe dysfunction.13 
 As with all pharmacological interventions, side effects are a crucial factor and 
should not be ignored. Researchers found that growth failure, delayed bone maturation, 
and delayed puberty were the most problematic side effects of corticosteroid treatment. 
After 1 year of treatment, all four remaining participants of the therapy group had 
experienced declined growth rates. At their last follow-up all had heights between 3.01 
and 4.77 standard deviations (SDs) below normal and had nearly reached their final 
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height based on yearly left hand x-rays for bone age. According to parent reports, short 
stature and growth failure remained a major concern of corticosteroid treatment.13 
Researchers explain that excessive weight gain and development of cushingoid 
features are the most common side effects of daily corticosteroid therapy.6,18 They 
continue by declaring that with their alternate day regimen “cushingoid features were not 
observed, and weight gain was limited.” Three of the four participants in the treatment 
group were overweight in childhood until the ages of 13-15 (indicated by BMI). 
Although weight gain was not a major negative finding, body fat percentages measured 
by DXA scan was. There was a mean total fat mass of 36.7% in the four remaining 
therapy participants (compared to 10.5% in healthy children) by the age of 8 that 
continued to increase to a mean value of 60% by the last follow-up. For these reasons, 
investigators argue that DXA should be used over BMI as the method of choice for 
assessing weight gain and obesity in DMD research.13 
Bone age was chosen as a method of assessing degree of maturation. Bone age 
was delayed in all patients until puberty was reached, and the timing of onset of puberty 
was related to bone age more than chronologic age. Researchers clarify that onset of 
puberty for boys is considered normal if between the ages of 9 and 13.5 years.19 Puberty 
was so delayed in this participant population that by the ages of 14-15, three of the four 
treated participants required androgen treatment (testosterone 50 mg/monthly) to induce 
puberty. It was noted that at the end of androgen therapy, participants had a completely 
normal hormonal profile. Catch up growth during puberty is generally 25-30 cm in 
normal boys. However, all participants experienced less; approximately 10 cm in the 
three participants that required androgen therapy and around 14 cm in the patient with 
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spontaneous puberty. Investigators also commented that scoliosis was not detected in any 
participants based on clinical exam findings including the forward bend test (thus x-rays 
of spine were not performed). Although bone fractures were rare in this small sample of 
DMD patients on corticosteroids (one patient in the therapy group sustained an arm 
fracture during this study), low bone mineral density (BMD) and delayed bone 
maturation confirm the value of DXA and osteoporosis monitoring.13,20,21 
Ricotti et al Study 
 In addition to daily and alternate-day corticosteroid dosing regimens, intermittent 
dosing schedules (usually 10 days on and 10 days off) are another common option chosen 
for DMD treatment. In this prospective longitudinal observational study,14 data were 
collected from 17 pediatric neuromuscular centers in the UK. The 360 male participants 
included were between the ages of 3 and 15 with confirmed DMD. Participants were 
treated either with daily prednisolone or an intermittent schedule of 10 days on/10 days 
off. Investigators state that while daily corticosteroid therapy is believed to be the most 
effective, side effects are great and often a reason for noncompliance or discontinuation. 
For this reason other regimens have been suggested and intermittent dosing schedules are 
a widely used alternative in the UK. The purpose of this study was to compare the 
benefits and adverse effects of daily versus intermittent prednisolone schedules.14 
 As mentioned, data from the 360 DMD participants were collected from 17 
participating specialist pediatric neuromuscular centers in the UK and compiled into the 
NorthStar database. In 2003 the NorthStar clinical network for pediatric neuromuscular 
disease (NSCN) was established allowing researchers to uniformly and systematically 
collect data from the various participating centers. Participants were aged 3-15 and were 
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assessed biannually. Included in this study were 136 patients in the daily corticosteroid 
regimen group and 154 in the intermittent group as well as 70 DMD boys that switched 
treatment schedules sometime during the study. The “switchers” were assigned to the 
group in which they spent the majority of the study duration (total of 191 on intermittent 
and 169 on daily prednisolone) and their data were analyzed in that group. DMD was 
genetically confirmed in each patient and parent or guardian consent was obtained. To 
ensure standardized assessments across all centers, physicians and physiotherapists 
underwent a national training program. Primary outcomes of interest included loss of 
ambulation (LOA) and the NorthStar Ambulatory Assessment (NSAA) score which will 
be described shortly and summarized in Box 1. Researchers were also interested in 
evaluating severity of side effects in both therapy groups.14 
 Researchers remind us that the progressive nature of DMD often leads to loss of 
ambulation by 9.5 years of age (range 6-12 years) if untreated.5 Corticosteroids have 
shown to slow the deterioration of muscle function and prolong independent 
ambulation.22 A Cox regression model was used for this study to compare loss of 
ambulation between the daily and intermittent therapy groups. Loss of ambulation was 
reported in 39/168 boys on daily therapy and 51/184 boys on the intermittent schedule 
during the course of this study. There were two participants who were never ambulant 
and six whose ambulation statuses were never known. These eight participants were 
excluded from this portion of the analysis (one participant from the daily group and seven 
from the intermittent group). The median LOA age in the daily corticosteroid group was 
14.5 years and 12 years for the intermittent group, however the authors state that the 
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difference in mean ages of LOA was not statistically significant (p=0.13). The hazard 
ratio (HR) for the intermittent vs daily therapy group was 1.57 (95% CI 0.87-2.82).14 
 In addition to LOA, investigators evaluated overall function in ambulant boys 
with DMD by assigning a score based on the NorthStar Ambulatory Assessment 
(NSAA). The NSAA consists of 17 different items that are ordered into one of three 
categories. If activities were carried out normally with no obvious modification 2 points 
were given, 1 point was given if the activity could be performed independently but with 
modified methods, or 0 points if the task could not be carried out. A total of 34 points 
were possible and the assessments were carried out in 20 minutes. The analysis of NSAA 
total scores illustrated a slower decline of function in the daily regimen group. Neither 
the daily group nor the intermittent group experienced a regression in NSAA scores 
before the age of 6. However, those in the intermittent regimen began demonstrating a 
decline in total scores by the age of 7 and the difference in NSAA scores between the two 
regimens increased by 1.58 points each year (95% CI 1.04 to 2.11).  Researchers also 
compared the NSAA total scores of participants that began corticosteroid therapy before 
the age of 5 to those who initiated therapy after the age of 5 years. An overall trend in 
favor of beginning therapy before the age of 5 may exist (difference of 3.04; 95% CI 0.15 
to 6.23; p=0.06).14 
 Respiratory and cardiac outcomes did not differ between the daily and 
intermittent corticosteroid schedules. When the participants were analyzed as a whole, 
researchers were able to conclude that the mean FVC and LVSF values remained within 
normal limits. Despite remaining in normal limits, there was a significant progressive 
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decline in FVC% by 2.2% each year after the age of 10 years (p<0.001). LVSF% also 
declined by 1% each year after the age of 12 years (p<0.001).14 
 The authors of this study were very interested in comparing the severity of side 
effects of daily and intermittent corticosteroid regimens. They concluded that moderate 
and severe side effects were more frequent in the group treated with daily corticosteroids 
(Table 2) after evaluating biannual assessments and parental reports. There were 
statistically significant higher rates of cushingoid features, hyperactivity, GI symptoms, 
hypertension, height restriction, decreased bone mineral density, and vertebral fractures 
in those in the daily corticosteroid group.14 
Height restriction, or growth failure, is a common side effect of long-term 
corticosteroid use. Participants in the daily therapy group had significantly lower mean 
height z-scores, the authors reported a difference in z-scores of 1.09 (95% CI 0.78 to 
1.40; p<0.001) even when adjusted for length of time on corticosteroid therapy. The 
mean difference in baseline BMI was significantly higher in the daily treatment group as 
well; mean difference of 0.43 (955 CI 0.11 to 0.74; p<0.01). Researchers found BMD to 
be compromised in both treatment groups but, again, more so in those treated with daily 
corticosteroids. They observed that 8% of participants in the daily group had a BMD z-
score < -2.5 on dual-energy x-ray absorptiometry (DEXA) scan in comparison to only 5% 
in the intermittent group. Vertebral fractures, defined as vertebral wedging on lateral 
spine radiography by the NSCN, were reported in twice as many cases in the daily group 
when compared to the intermittent (8% and 4% respectively).14 
Straathof et al Study 
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In their retrospective observational study, Straathof et al15 analyzed data from 35 
patients with DMD treated with intermittent dosing of prednisone. Participants were boys 
with DMD confirmed by DNA analysis whose parents consulted the De Trappenberg 
rehabilitation center for treatment with corticosteroids. Of the 43 boys with DMD that 
consulted the center between 1996 and 2005, 35 met inclusion criteria and had been 
treated with intermittent corticosteroid therapy and were thus included in the study. 
Participants had been treated with prednisone 0.75 mg/kg in an alternating schedule of 10 
days on followed by 10 days off. After they lost ambulation the dose was lowered to 0.3-
0.5 mg/kg still in an intermittent 10 days on then 10 days off regimen. Prednisone therapy 
was initiated while participants were still ambulatory at a median age of 6.5 years (range 
3.5-9.7 years). Participants were assessed by the rehabilitation physician as well as a 
pediatrician every six months. Investigators focused their evaluations on motor skills and 
side effects of the corticosteroid treatment. Timed tests were performed at each 
evaluation including 10-m fast walk or run and time to stand from sitting position on the 
floor without assistance. Clinical exams were performed to monitor height, weight, and 
blood pressure (BP). X-rays of the spine were also performed each year to monitor any 
development of scoliosis and to screen patients for vertebral fractures.15 
Investigators defined loss of ambulation as the inability to walk indoors 
unsupported. LOA was reported at a mean age of 10.9 years (median age of 10.8 years) 
with a 95% CI 10.0-11.8 years. The researchers explain that in similar studies those 
treated with daily corticosteroids lost the ability to independently ambulate at the mean 
ages of 11.5 and 12.5 years.15 
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During the course of this study, two patients being treated with prednisone 
required scoliosis surgery at the ages of 13.5 and 8 years. The first patient had used 
prednisone for only 9 months until he required the use of wheelchair at the age of 9.9 
years. The second patient had sustained a femur fracture that left him requiring the use of 
a wheelchair at the age of 6.5 years. While respiratory function was evaluated and no 
child required respiratory support during this study, it was not a focus or primary 
outcome of interest to this study.15 
Side effects were closely monitored and were the primary reason for 
discontinuation of therapy in five patients. Weight gain on the weight-to-height growth 
chart was observed in 46% of participants but none of the ambulatory boys experienced 
weight gain > 1.0 SDS. Studies looking at daily corticosteroid dosing found 75% of 
participants experienced weight gain >10%.23,24 This study reports that only 25% of their 
intermittently treated participants experienced comparable weight gain and the greatest 
weight gain was in patients who had lost ambulation and required the use of a wheelchair. 
During corticosteroid therapy eight participants sustained a fracture; a traumatic fall was 
responsible in six of those eight cases and the cause of fracture was unknown in the 
remaining two boys. Four of the patients suffered femur fractures that left them requiring 
use of a wheelchair, two had forearm fractures, and the remaining two sustained lower 
leg fractures. The majority of patients in this study had blood pressures that remained 
<95% percentile for their age and height during the follow-up period. There were 3 
patients that had elevated BPs >95% percentile on one occasion. Two of the participants 
were found to have decreased ejection fractions on echocardiogram and required 
treatment with an ace inhibitor. The first boy was 10 years old and has used prednisone 
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for 5 years. The second was 13 years old and had used prednisone for 7.5 years. The third 
participant with an elevated BP reading had stopped taking corticosteroids 3 years prior 
but was given digoxin by his cardiologist. Follow-up data on this participant was 
limited.15 
DISCUSSION 
 
While the medical community acknowledges corticosteroids as the mainstay of 
treatment for DMD, the optimal dosing regimen and age to initiate therapy has not been 
established. Currently, corticosteroids are “offered for boys 5 years of age or older who 
are no longer gaining motor skills, or whose motor skills are declining.”8 Based on the 
current research, daily corticosteroid therapy (prednisone 0.75 mg/kg or deflazacort 1.0 
mg/kg) appears to be the most beneficial in prolonging ambulation and slowing 
progression of DMD while delaying respiratory decline and onset of scoliosis.6,12 
Investigators of the Ricotti et al14 study argue that there was no statistical significance in 
the median LOA age between those treated with daily corticosteroids when compared to 
those treated intermittently. However, increased ambulation of 2.5 years (median LOA 
for daily treatment was 14.5 years and only 12 years for those treated with intermittent 
dosing) is clinically meaningful to young boys with DMD as ambulation is a significant 
factor in quality of life. Research shows that DMD boys on long-term corticosteroid 
treatment have an extension of greater than 3 years’ independent ambulation in 
comparison to untreated patients as well as a significantly decreased risk of developing 
scoliosis.7 However noncompliance and discontinuation of therapy are not uncommon 
secondary to adverse effects of corticosteroid treatment especially in those treated with 
daily regimens. 
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Age at which corticosteroid therapy is initiated appears to play a significant role 
in delaying loss of ambulation. Ricotti et al14 found that participants who started 
treatment before the age of 5 had a slower decline in functional abilities, strength and 
mobility. Researchers were able to conclude that the NSAA total scores for the 
intermittent corticosteroid regimen group deteriorate faster than those on daily 
corticosteroids after the age of 7 at a rate of -1.58 points per year. However, participants 
that started therapy before the age of 5 had a slower decline in their NSAA scores than 
those who initiated corticosteroid therapy after 5 years of age.14 While there appears to 
have been little success associated with intermittent dosing schedules, Merlini et al13 had 
great success with prolonged ambulation in its participants that began alternate-day 
corticosteroid therapy between the ages of 2-4 years. At the last follow-up evaluation, the 
four patients treated with alternate-day prednisone initiated between the ages of 2 and 4 
years were still fully ambulant (ages 16-18) and three were still able to climb stairs.13  
All these studies12-15 provide evidence for the benefits of corticosteroids in 
treatment of DMD, yet all have limitations. There are few RCT studies comparing 
efficacy of various corticosteroid regimens or initiation age of therapy. Loss of follow-up, 
small sample sizes, subjective measurements of end points, and the observational nature 
of studies are common limitations associated with the current studies assessing efficacy 
of corticosteroids in treatment of DMD. The four studies included in this review were 
retrospective observational in nature, thus lowering their overall quality with respect to 
the GRADE criteria. Although the Merlini et al study13 had a complete and lengthy 
follow-up, the entire control group was lost during that time and researchers were unable 
to compare results of the treatment group to a control group resulting in a serious 
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limitation of the study. Three of the four studies12,13,15 had imprecision issues secondary 
to small sample sizes, a common inadequacy of many studies assessing efficacy of 
various corticosteroid regimens in DMD patients. While the Ricotti study14 incorporated 
a decently sized sample population, the authors allowed participants to switch therapy 
groups during the course of the study. The researchers analyzed the participants in the 
therapy group in which they spent the majority of the study duration; however the 
inappropriate handling of participants switching between treatment and therapy groups 
created an inconsistency limitation that further downgraded the quality of this study. All 
data collected for the Straathof et al study15 was collected from one rehabilitation center 
thus increasing the risk of bias. The subjective measurement and collection of outcomes 
and data was a limitation of several studies. Researchers of the Merlini et al study13 
monitored patients for scoliosis with clinical exams and forward bending tests but no 
objective screening modalities were used. Similarly, authors of the Ricotti et al study14 
admit that their study faced challenges associated with subjective collection of data and 
parental reports. When assessing study quality with respect to prolonged ambulation, 
normal respiratory function, and delayed onset of scoliosis, all studies12-15 included in this 
review received an overall quality rating of very low because of the various limitations 
previously discussed.  
More subtle limitations are identified in these studies. Researchers of the Yilmaz 
et al study12 found that muscle strength was lower in the therapy group but question 
whether or not the decreased muscle strength in the therapy group was a result of 
neglected stretches rather than a detrimental effects of corticosteroid treatment. This 
confounder could very well explain the difference in muscle strength between the two 
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groups despite the therapy group remaining ambulatory longer. Participants in both 
studies evaluating efficacy of alternate-day corticosteroid dosing12,13 were also given 
vitamin D supplementation as well as a calcium rich diet or calcium supplementation. 
The role and effects of such supplementation should have been discussed as they may 
alter outcomes or side effects of treatment. 
Researchers continue searching for the optimal dosing schedule. A recent 
randomized blinded trial of weekend vs daily prednisone in 64 DMD boys illustrates a 
possible new option for treatment. Participants in this study were treated with either daily 
prednisone (0.75 mg/kg/day) or weekend prednisone (5 mg/kg Saturday and Sunday) for 
12 months. Weekend dosing appeared to be equally beneficial in preserving muscle 
strength when compared to the daily therapy. The two regimens were equally tolerated 
with respect to side effects; however, those in the weekend dosing group had significantly 
greater linear growth.25 
Before a definitive answer can be given as to which regimen is best and what age 
to initiate therapy, a long-term randomized clinical trial comparing several dosing 
regimens beginning at various ages should be performed. Future studies require 
internationally standardized endpoints that can be objectively measured. For example, it 
is both difficult and non-standardized when objectively defining non-ambulatory status, 
measuring cushingoid features, calculating reduction in height potential, and quantifying 
behavioral problems. An international clinical trial comparing various corticosteroid 
regimens in young corticosteroid naïve patients in a randomized controlled trial is 
currently underway (funded by NIH) and will hopefully shed light on the questions that 
remain.26 
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CONCLUSION 
Corticosteroids play a significant role in prolonging ambulation, slowing 
progression of DMD, and delaying onset of scoliosis as well as respiratory decline. “The 
age at which ambulation is lost is a clinical meaningful endpoint for evaluating the 
efficacy of treatment in DMD patient.”15 Current research confirms corticosteroids 
prolong independent ambulation beyond the mean age of 9.5 years associated with the 
natural course of DMD. Daily corticosteroid therapy (prednisone 0.75 mg/kg/day or 
deflazacort 0.9 mg/kg/day) has demonstrated to be the most effective dosing regimen for 
prolonging independent ambulation and slowing the progression of DMD. While 
evidence supports daily therapy to be most effective, moderate to severe adverse effects 
were more frequent in those treated daily corticosteroids. Alternative dosing schedules 
(including alternate-day, intermittent, or weekend dosing regimens) are an option that 
many parents are choosing for their boys with DMD. These alternative options also 
prolong ambulation and decelerate progression of DMD but not to the extent that daily 
corticosteroid therapy does. Parents often choose or switch to these regimens as they are 
associated with less severe side effects. It is important to consider ADRs when choosing 
a treatment regimen but prolonged ambulation and quality of life are the most important 
factors to consider in patients with this disorder as early death will  ensue. Allsop and 
Ziter explain that the important thing to consider when discussing DMD treatment is the 
ability of children to preserve functioning and performing activities (1981).27 
Evidence may suggest that even more important than dosing schedule is the age at 
which therapy is initiated. “As long-term corticosteroid treatment is effective in 
prolonging function but not in recovering lost function, its early use seems appropriate.”13 
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There is not enough data currently and too few randomized controlled trials to 
definitively reach a conclusion, but beginning treatment before significant deficits in 
motor function are detected (ages 2-4) seems to offer superior functional benefit. The 
overall combined quality of these studies is very low based on the GRADE criteria, 
primarily because of the observational nature of all studies and small sample sizes. There 
is a need for further randomized controlled studies that compare all dosing regimens 
head-to-head as well as different ages at which therapy is initiated. 
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TABLE 1  Characteristics of Reviewed Studies  
GRADE Quality Assessment  
Importance  Downgrade Criteria 
Quality 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication bias 
likely 
Prolonged Ambulation   
4 
 
4 
Observational 
 Serious 
limitationsa 
No serious 
indirectness 
Very serious 
imprecisionb 
Serious 
inconsistenciesc 
Possible 
publication bias 
Very 
Low 
Critical 
Normal Respiratory Function   
2 
2 
Observational 
Serious 
limitationsa 
No serious 
indirectness 
Serious 
imprecisionb 
Serious 
inconsistenciesc 
No bias likely  
Very 
Low 
Critical 
Delayed Onset of Scoliosis   
2 
2 
Observational 
Serious 
limitationsd 
No serious 
indirectness 
Very serious 
imprecisionb 
No serious 
inconsistencies 
No bias likely  
Very 
Low 
Critical 
GRADE: Grading of Recommendations, Assessments, Development and Evaluation. 
 
a Control group lost to follow-up in the Merlini et al study 2 Study is lacking objective measurement of scoliosis. 
b Yilmaz et al study,1 Merlini et al study,2 and Straathof et al study 4 consisted of a small sample sizes 
c Ricotti et al study3 allowed for inconsistent handling of switching between treatment and control groups 
d Data collected for the Straathof et al study 4 was gathered from only  one rehabilitation center (increasing risk of bias) 
 
 
Table 2. Merlini et al Study Data 
                     Age at           Age at              Age at                Age at         10-m walk        FVC (ml)  
                   onset of             last              rising from        climbing           speed at          and % of 
                  treatment       follow-up            floor            stairs unable       follow-up        predicted 
Patient       (years)           (years)          unable (years)        (years)              (m/s)           at follow-up 
1 3.9 18.5 15.5 NA 1.25 2470 (73%) 
2 4.0 18.6 12.5 17.0 1.11 2130 (65%) 
3 2.4 16.1 NA NA 1.0 2610 (107%) 
4 3.3 17.0 NA NA 1.01 2250 (96%) 
Mean 3.4 17.6   1.1  
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Table 3. Side Effects of Daily vs Intermittent Dosing Regimens 
 Daily Intermittent X2 p value 
Cushingoid Features 33% 15% <0.01 
Hyperactivity 23% 15% 0.05 
GI symptoms 14% 6% 0.01 
Hypertension 22% 5% <0.01 
Temper Tantrums 40% 28% 0.02 
Insomnia 11% 4% 0.01 
Mood swings 38% 29% 0.08 
Aggressiveness 29% 21% 0.09 
Vertebral fractures 8% 4% 0.1 
BMD z-score <-2.5 8% 5% 0.1 
 
 
Box 1   The 17 Items Included in the NorthStar 
Ambulatory Assessment 
Stand                                                                  Gets to sitting 
Walk                                                                   Rise from the floor 
Stand up from chair                                            Lift head 
Stand on right leg                                                Stand on heels 
Stand on left leg                                                  Jump 
Climb box step – right leg                                   Hop – right leg 
Climb box step – left leg                                     Hop – left leg 
Descend box step – right leg                                (Run 10 m) 
Descend box step – left leg 
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